Abbott Laboratories stock gains as Norges Bank acquires new institutional position

Traders Union
All News
Financial News
Abbott Laboratories gains 3.67% today

Highlights

Bank of New York Mellon increased its Abbott Laboratories stake by 2% to 12,926,170 shares worth $1.62 billion, reflecting escalating institutional confidence.
Major asset managers, including Norges Bank with a new $2.94 billion position and Alliancebernstein boosting holdings by 51%, signal strong liquidity absorption in Abbott.
Technical signals are broadly bullish with short-term momentum highs, but overbought indicators and expected price range of $88.93–$93.76 suggest cautious positioning.

Institutional buying accelerates as major asset managers boost stakes

Bank of New York Mellon Corp has increased its holding in Abbott Laboratories by 2.0% during the fourth quarter, now holding approximately 12,926,170 shares valued at $1.62 billion, according to its latest filing with the SEC. This net institutional accumulation signals robust demand and rising confidence in the company as sizable positions are added to major portfolios. Significant buying activity is further supported by Norges Bank's new $2.94 billion stake and a 51.0% boost in Alliancebernstein L.P.'s holdings, pointing to strong liquidity absorption and sustained appetite from top asset managers.

Overbought signals rise as buyers sustain control above support

On the technical front, ABT/USD is trading above both its MA-20 ($87.68) and MA-50 ($86.78), while still positioned below the longer-term MA-200 ($115.95) on the daily timeframe. The Ichimoku Kijun provides near-term support at $88.37. Momentum indicators are generally positive: MACD and ADX show a buy bias, RSI stands elevated at 69.54 and is nearing overbought territory, CCI is overbought, and Stoch RSI reads neutral. Bull/Bear Power is overbought, confirming buyer dominance intraday, while the Awesome Oscillator reinforces the prevailing upward tone. Overbought signals from CCI and BBP suggest caution is warranted for aggressive new positions.

Limited downside risk as price poised near resistance zone

Short-term price action is likely to remain within the $88.93 to $93.76 range, aligning with typical volatility relative to current levels. The probability of further gains is assessed as very high, while downside risk appears limited in the near term. The base case sees ABT holding within this range, with a breakout above resistance opening room for additional upside, and a breakdown below immediate support indicating a possible pullback.

Anton Kharitonov, analyst at Traders Union, sees Abbott Laboratories supported by strong institutional inflows, but remains cautious. Price action is strong above key moving averages, though overbought signals and proximity to resistance call for careful risk management. Base case holds for consolidation between $88.93 and $93.76, with any sustained break below immediate support signaling a potential reversal. "Until buyers prove they can hold above resistance, I remain defensive and mindful of near-term downside risks."

Earlier, analysts noted that Abbott Laboratories was experiencing a conflict between short-term bullish momentum and persistent longer-term bearish pressure. The current influx of institutional buying and a broadly improved technical picture now meaningfully shifts the balance toward sustained upside, making a decisive break above the $93.76 resistance level a pivotal trigger for renewed bullish continuation.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.